TGA / PMDA / NMPA · Asia-Pacific
immunotherapy — TGA / PMDA / NMPA regulatory status
immunotherapy regulatory status in the Asia-Pacific is tracked from public TGA / PMDA / NMPA records and cross-linked clinical and patent datasets on NovaPharmaNews. Current status: NMPA clinical trials.
Status snapshot
- Status
- NMPA clinical trials
- Structured fields
- 4
Regional decision snapshot — NMPA: clinical trials.
Linked evidence on this spoke: 37 published clinical programs and 12 related patent records. Use the tables below for NCT identifiers, phases, and exclusivity dates; verify against primary sources before BD or medical decisions.
Regulatory timeline
| Regulator | Region | Status | Date | Source |
|---|---|---|---|---|
| NMPA | China | clinical trials | — | Evidence |
Linked clinical programs
| Program | Phase | Sponsor | NCT |
|---|---|---|---|
| Adjuvant immunotherapy | Phase 3 | Chinese Academy of | NCT05877872 |
| Autologous Dendritic Cell-Tumor Cell Immunotherapy (DC-TC) | Phase 3 | Lisata Therapeutics | NCT01875653 |
| DIDaC/ NVALT35 | Phase 3 | Disc Medicine | 2025-520792-67-00 |
| Dendritic cell immunotherapy | Phase 3 | NORTHWEST BIOTHERAPEUTICS | NCT00045968 |
| Dendritic cell immunotherapy | Phase 3 | NORTHWEST BIOTHERAPEUTICS | NCT00043212 |
| UC-IMM-2101 | Phase 3 | Ningbo Cancer Hospital | 2024-513707-14-00 |
| Visilizumab | Phase 3 | First People's Hospital | NCT04722952 |
| adoptive immunotherapy | Phase 3 | Chinese PLA General | NCT02851784 |
| CCM-RNT-202402 | Phase 2 | Kyverna Therapeutics | NCT06590545 |
| Cadonilimab | Phase 2 | Second Affiliated Hospital | NCT05901584 |
| Cadonilimab | Phase 2 | First People's Hospital | NCT05901584 |
| Chemotherapy + immunotherapy | Phase 2 | Hunan Province Tumor | NCT05584267 |
Related patents
| Number | Title | Jurisdiction |
|---|---|---|
| 12414983 | CD200AR ligands for cancer immunotherapy | US |
| 12384830 | Compositions and methods for improving immunotherapy | US |
| 12338459 | DNA-chimeric antigen receptor T cells for immunotherapy | US |
| 12329816 | Immunotherapy with metabolic enzyme expression | US |
| 12311030 | Antibody-sting agonist conjugates and their use in immunotherapy | US |
| 12303551 | Cellular immunotherapy compositions and uses thereof | US |
| 12297509 | Biomarkers for predicting tumor response to and toxicity of immunotherapy | US |
| 12280140 | Processes for production of tumor infiltrating lymphocytes and uses of the same in immunotherapy | US |
| 12275955 | Combining iPSC derived effector cell types for immunotherapy use | US |
| 12230378 | Systems and methods for coordinating manufacturing of cells for patient-specific immunotherapy | US |
| 12226434 | Processes for production of tumor infiltrating lymphocytes and uses of same in immunotherapy | US |
| 12230379 | Systems and methods for coordinating manufacturing of cells for patient-specific immunotherapy | US |
Related hubs
FAQ
What is the TGA / PMDA / NMPA approval status of immunotherapy?
immunotherapy currently shows NMPA clinical trials in our Asia-Pacific regulatory index. Confirm on the official TGA / PMDA / NMPA label or EPAR before clinical or commercial use.
Where does NovaPharmaNews get immunotherapy regulatory data?
Status fields are joined from public sources (openFDA / EMA / regional agencies), ClinicalTrials.gov-linked programs, and patent registries. See /about/data-sources for attribution.
How many clinical programs are linked to immunotherapy?
This spoke lists 37 published programs associated with immunotherapy in our pipeline index.